A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007
At a glance
Conditions
NCT05509855
Where you'd take part
This study runs at 5 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Children's Hospital of Philadelphia
Philadelphia, Pennsylvaniano site contact published
Childrens Hospital LA
Los Angeles, Californiano site contact published
City of Hope
Duarte, Californiano site contact published
Peter MacCullam Cancer Center
Melbourne, Australiano site contact published
Washington University
St Louis, Missourino site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Cherry Thomas, MD · STUDY_DIRECTOR · Allotera Therapeutics
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Delayed adverse events (AEs)/serious adverse events (SAEs)up to 15 years
assess the risk of delayed adverse events including serious events following exposure to WU-CART-007
- Persistence of WU-CART-007 cellsEvery 6 months for up to 5 years and then yearly for up to 15 years
Peripheral blood samples will be monitored used polymerase chain reaction for persistence of WU-CART-007 cells
- Tanner Stagingup to 15 years
Tanner Staging will be used to evaluate growth and development outcomes and sexual maturity status for patients who were \< 18 years of age at the time of treatment with WU CART-007